Co-Authors
This is a "connection" page, showing publications co-authored by Paola Fioretto and Angelo Avogaro.
Connection Strength
1.426
-
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother. 2017 Apr; 18(5):517-527.
Score: 0.709
-
Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19. Diabetes Res Clin Pract. 2020 10; 168:108449.
Score: 0.226
-
Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab. 2020 10; 22(10):1946-1950.
Score: 0.223
-
Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis. Intern Emerg Med. 2021 Mar; 16(2):419-427.
Score: 0.057
-
The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost. 2020 Oct; 18(10):2629-2635.
Score: 0.056
-
Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020 Oct; 168:108374.
Score: 0.056
-
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. Int J Cardiol. 2020 10 01; 316:280-284.
Score: 0.055
-
Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017 Aug 15; 241:450-456.
Score: 0.044